To calculate the efficacy and safety of ABT-493/ABT-530 for HCV genotype 2 in Japan,Randomised non-blinded multicenter trial.
Not Applicable
Completed
- Conditions
- HCV genotype 2
- Registration Number
- JPRN-UMIN000022569
- Lead Sponsor
- Shinshu University of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 1
Inclusion Criteria
Not provided
Exclusion Criteria
HCC
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method SVR with 12 weeks after treatment
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms of ABT-493 and ABT-530 in targeting HCV genotype 2 replication?
How does the efficacy of ABT-493/ABT-530 compare to standard-of-care regimens for HCV genotype 2 in Japan?
Which biomarkers are associated with treatment response to ABT-493/ABT-530 in HCV genotype 2 patients?
What adverse events were observed in the CERTAIN-2 trial of ABT-493/ABT-530 for HCV genotype 2?
Are there combination therapies involving ABT-493/ABT-530 that improve outcomes for HCV genotype 2 infection?